Anthem Biosciences
NSE: ANTHEM · ISIN INE0CZ201020 · Healthcare
₹963.00+20.65 (+2.19%)
Monday 9 November, 12:05 IST. Delayed. Source: Yahoo Finance.
Price chart
₹963.00 +20.65 (+2.19%) today
The day
- Previous close
- ₹942.35
- Open
- ₹949.80
- Day high
- ₹989.10
- Day low
- ₹946.50
Listed on NSE since 21 July 2025.
Key numbers
- Market value
- ₹51,594 Cr
- P/E (trailing)
- 84.62
- EPS (trailing)
- ₹10.82
- Price to book
- 15.74
- Dividend yield
- 0.22%
- Return on equity
- 20.4%
- Debt to equity
- 0.01
- Profit margin
- 29.7%
- Volume today
- 12.92 L
- Average volume
- 6.82 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹1,056.92 Cr | ₹385.19 Cr |
| FY24 | ₹1,419.37 Cr | ₹367.31 Cr |
| FY25 | ₹1,844.55 Cr | ₹451.26 Cr |
| FY26 | ₹2,124.33 Cr | ₹591.79 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹594 Cr | ₹0 | – |
| Q1 FY27Apr–Jun 2026 | ₹418 Cr | ₹0 | – |
| Q4 FY26Jan–Mar 2026Audited | ₹611 Cr | ₹190 Cr | – |
| Q3 FY26Oct–Dec 2025 | ₹423 Cr | ₹0 | – |
| Q2 FY26Jul–Sep 2025 | ₹550 Cr | ₹0 | – |
| Q1 FY26Apr–Jun 2025 | ₹540 Cr | ₹0 | – |
Source: Anthem Biosciences’s results filed with NSE, consolidated (the whole group). Net profit is the share of Anthem Biosciences’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹1,074 Cr | ₹1,045 Cr |
| Investments | ₹1,261 Cr | ₹1,007 Cr |
| Inventories | ₹189 Cr | ₹125 Cr |
| Owed by customers | ₹530 Cr | ₹594 Cr |
| Cash and equivalents | ₹20 Cr | ₹273 Cr |
| Total assets | ₹3,686 Cr | ₹3,429 Cr |
| Borrowings | ₹39 Cr | ₹51 Cr |
| Total liabilities | ₹405 Cr | ₹387 Cr |
| Shareholders’ equity | ₹3,281 Cr | ₹3,043 Cr |
Source: Anthem Biosciences’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Anthem Biosciences
Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development batches of molecules used for clinical trials up to commercial manufacturing for small molecules and biologics. It also manufactures and sells specialized fermentation-based active pharmaceutical ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company was incorporated in 2006 and is based in Bengaluru, India.
- Industry
- Biotechnology
- Based in
- Bengaluru
- Employees
- 2,282
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Anthem Biosciences in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 2 Per Share
Dividend · ex-date 25 June 2026 · record date 26 June 2026
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.